Company ProfilePremium

Integral Diagnostics Limited

Company Profile Analysis

Ticker: IDX.AX

ESOMAR 23 Corporate BadgeISO Certifications Badge
Integral Diagnostics Limited - Company showcase

Year Founded & Workforce

2008

3,049 Employees

Integral Diagnostics Limited logo

Integral Diagnostics Limited Employee Contacts

We don't hold contact details for this company yet — you can request them.

Request Employee Contacts

Integral Diagnostics Limited Overview

Integral Diagnostics is an Australasian diagnostic imaging services group operating 142 clinics (62 of them "comprehensive" full-modality sites) across Victoria, Queensland, Western Australia, Tasmania, South Australia and New Zealand, supported by 468 reporting radiologists and a fast-growing teleradiology arm, IDXt. Following its December 2024 scrip merger with Capitol Health, IDX describes itself as having the second-largest clinic network in Australia, with roughly a 12% share of the national diagnostic imaging market and around 19% in its key operating states. Revenue is overwhelmingly derived from fee-for-service imaging reimbursed by Medicare plus patient gap fees, supplemented by hospital reporting contracts and teleradiology. Its differentiating claim is a "medical leadership model" that embeds radiologists in governance, including a radiologist on the board. In FY26 it generated A$788.7m of revenue, A$164.8m of operating EBITDA (20.9% margin) and A$47.4m of operating NPAT, and is now in a leadership transition under new CEO Jason Martinez.


Company's own description (FY26 Annual Report, paraphrased)

IDX describes itself as a leading provider of medical diagnostic imaging services in Australia and New Zealand that uses non-invasive imaging technologies to create images of bones, tissues and organs to diagnose and treat illness and injury. Its modalities are MRI, nuclear medicine (including PET), CT, mammography, ultrasound and radiography (X-ray and EOS). It serves referrers — general practitioners, dental practitioners, medical specialists and allied health professionals — and their patients. Comprehensive sites offer the full modality range and are generally located with or near major specialist referrers who require higher-complexity imaging. Its stated vision is "a healthier world" and its purpose is to deliver the best health outcomes for patients; its corporate tagline is that good medicine is good business.

Independent characterisation

IDX is a capital-intensive, labour-intensive, reimbursement-driven healthcare services business. The economic engine is: (1) referral capture from GPs and specialists; (2) conversion of referrals into imaging examinations on owned equipment; (3) radiologist reporting; and (4) billing to Medicare (bulk-billed) or Medicare plus a patient out-of-pocket gap. Three structural profit levers dominate:

  1. Modality mix. CT, MRI and PET carry far higher fees per exam than X-ray and ultrasound. IDX's average fee per exam in Australia rose 6.5% in FY26 against Medicare indexation of only 2.4%, the difference being mix shift toward higher-end modalities (FY26 Annual Report).

  2. Radiologist productivity. Radiologists are the scarcest and most expensive input. Teleradiology (IDXt, ~15% of scans) and AI tools (~10% of scans) are deployed to raise reports per radiologist (FY26 Annual Report, Industry and Regulatory Outlook).

  3. Fixed-cost leverage. Rent, equipment and staffed rosters are largely fixed; incremental volume through existing sites expands margin. Group operating EBITDA margin moved from 19.3% (FY23) to 20.9% (FY26).

Revenue model mix

Revenue streamDescriptionDisclosure status
Fee-for-service imaging (Medicare + patient gap)Core revenue; Medicare Benefits Schedule rebates plus out-of-pocket fees; bulk billing for some patientsDominant; exact % not publicly disclosed
Reporting contractsFixed-rate or per-report contracts with hospitals (public and private)Included in "average fees per exam (including reporting contracts)"; separate revenue not disclosed
Teleradiology (IDXt)Urgent, routine and overflow reporting for IDX, private practices and public hospitals across all Australian states and NZRevenue not separately disclosed; reported ~15% of IDX Australian revenue at FY24 (FY24 Results release); reporting volumes up >30% in FY26
National Lung Cancer Screening Program (NLCSP)Government-funded low-dose CT screening from 1 Jul 2025~14% national share of screens in FY26; revenue not disclosed
New Zealand private and publicly outsourced imagingPrivate insurance, ACC, self-pay and public outsourcing (NZ has no Medicare equivalent)NZ revenue not separately quantified in sources reviewed

There is no product, subscription or licensing revenue of significance; IDX is a pure services business.

Value-chain position

IDX sits in the provider layer: it buys equipment (from global OEMs such as Siemens Healthineers, GE HealthCare, Philips, Canon — specific supplier contracts not disclosed), leases premises (right-of-use assets A$228.5m at 30 Jun 2026), employs clinical staff, and bills payers. It does not manufacture equipment or develop software at scale.

Customers and end-markets

Customer / referrer typeRole
General practitionersLargest referral base, especially legacy Capitol (Melbourne metro community imaging); sensitive to GP attendance trends
Medical specialists (orthopaedic, oncology, cardiology, neurology, breast)Drive high-acuity CT/MRI/PET volumes at comprehensive sites
Dental practitionersOPG/cone-beam dental imaging
Allied health (physiotherapists etc.)Musculoskeletal imaging
Hospitals (public and private)Reporting contracts, co-located practices (e.g., Eastwood Private Hospital, Maroochy Private Hospital)
Elite sportImaging @ Olympic Park (Melbourne) musculoskeletal centre of excellence
Patients1.757m patients seen in FY26; 4.099m exams
Referrer count>70,000 referrers in FY26

Strategy

Stated strategy (FY26 Annual Report, themes)

Strategic priorityThemeInitiatives
Core Growth & OptimisationExecute within the platformOrganic volume growth; modality mix optimisation; operating productivity; margin improvement; referrer and patient growth
Network ExpansionDisciplined, selective growthMRI deregulation opportunities; greenfields; brownfield expansion; hospitals and partnerships; scale IDXt; disciplined capital allocation
People & CultureCapacity, capability and cultureRadiologist attraction and retention; One IDX culture; leadership capability; engagement, safety and wellbeing
Transformation & InnovationBetter pathways and productivityPatient and referrer experience; digital pathway transformation; AI and technology enablement; data and workflow optimisation; adjacent growth

Vision: a healthier world. Purpose: deliver the best health outcomes for patients.

Values: patients first; medical leadership; one team; create value; integrity and excellence; embrace change.

Targeted outcomes: sustainable revenue growth; operating EBITDA margin >21.0%; increased productivity and capacity; improved patient access; de-gearing.

New CEO's agenda (Martinez letter, Aug 2026)

  • A 90-day clinic-by-clinic review of business, clinical, technology and cultural foundations (running roughly August to early November 2026).

  • Three initial focus areas: (1) operating margin — income-stream optimisation, labour cost management, radiologist productivity via technology, capex discipline; (2) clinician recruitment and retention; (3) culture and values.

  • Development of an updated strategic plan with the board, underpinned by a technology roadmap, explicitly targeting the July 2027 full MRI deregulation opportunity using IDX's scale.

Initiatives in the last 24 months

InitiativeStatus / metricSource
Capitol Health merger integration"Largely complete"; synergies A$14.0m+ vs ≥A$10m original targetFY26 Results
Group procurement functionSavings ahead of plan; further procurement efficiencies targeted in FY27FY26 Annual Report
IDXt scale-up80 contracted radiologists (Aug 2024) → 114 (Jun 2025) → 124 (Dec 2025) → 143 (Jun 2026)FY24, FY26 releases
MRI licence expansion23 → 42 licensed MRIs in Australia from Jul 2025FY26 Annual Report
NLCSP participation~14% national share; ~21% in key statesFY26 Annual Report
Orthopaedic hospital practicesEastwood (SA) and Maroochy (Qld)FY26 Annual Report
GreenfieldsWangaratta, Launceston relocation, Armstrong Creek (under construction)FY26 Annual Report
Workforce programsRegistrar engagement, International Medical Graduate development, in-house sonographer/radiographer trainingFY26 Annual Report
System consolidationOngoing; delayed 2026 engagement survey to Nov 2026FY26 Annual Report
AI governance frameworkRisk-tiered assessment of AI use casesFY26 Annual Report
DEI Strategy 2026–2028; first Reconciliation Action Plan due FY27In progressFY26 Annual Report
Debt hedging51.2% of gross debt hedged from late Dec 2025FY26 Annual Report
NZ strategic reviewReported in secondary source only (unconfirmed)Quartr summary

Guidance and medium-term targets

ItemGuidanceSource
FY27 replacement + growth capexA$50.0m–A$60.0mFY26 Results
Operating EBITDA marginImprove to >21.0% (no date specified)FY26 Results
LeverageTarget range 2.0x–2.5x net debt/EBITDA, trending downFY26 Annual Report
Dividend payout73% of operating NPAT in FY26 (no formal policy range extracted)FY26 Annual Report
FY27 revenue / earningsNo numerical guidance issued—

Products & Services

IDX sells services, not products; the "catalog" is a set of imaging modalities, sub-specialty services and service channels. Prices are set by the Medicare Benefits Schedule (MBS) rebate plus any out-of-pocket gap the practice charges; IDX does not publish a price list.

Imaging modalities

ServiceDescription / capabilityTarget referrer / patientPricing modelNotes
MRI (incl. 3T)Soft-tissue, neuro, MSK, prostate, cardiac MRISpecialists; GPs for eligible itemsMBS rebate (licence-dependent until full deregulation) + gap42 licensed MRIs in Australia from Jul 2025 (vs 23); full deregulation 1 Jul 2027
CTDiagnostic CT incl. low-dose lung screening CTGPs, specialists, NLCSPMBS + gap; NLCSP items~14% national NLCSP share in FY26
PET-CT / Nuclear medicineOncology staging, cardiac, neuroOncologists, specialistsMBS; PET excluded from FY26 2.4% indexationPET growth expected from NLCSP follow-ups; PET-CT greenfield at Noosa (Qld) and Cavendish (NZ)
MammographyScreening and diagnostic breast imagingGPs, breast surgeonsMBS + gapWomen's Imaging (Tas); breast sub-specialty in Vic Regional and NZ
UltrasoundGeneral, obstetric, gynaecological, vascular, MSKGPs, obstetriciansMBS + gapNZ business is the country's largest obstetric scan provider
X-ray (low-dose digital)General radiographyGPs, allied healthMBS, often bulk billedHigh-volume, low-fee
EOS imagingLow-dose full-body standing skeletal imagingOrthopaedic and spinal specialistsMBSListed in company modality list
Bone densitometry (DEXA)Osteoporosis assessmentGPsMBSPer company description (secondary source ROIC.ai)
Dental imaging (OPG, cone beam CT)Dental and maxillofacialDentistsMBS/privatePer company description (secondary source)
EchocardiographyCardiac ultrasoundCardiologistsMBSPer company description (secondary source)
Interventional radiologyImage-guided procedures, biopsies, injections, pain managementSpecialistsMBS + gapImaging @ Olympic Park integrates day procedures

Sub-specialty clinical services

Sub-specialtyWhere concentrated
Musculoskeletal / sports imagingImaging @ Olympic Park; Fowler Simmons (SA); orthopaedic hospital practices (Eastwood, Maroochy)
NeuroradiologyNew Zealand, Victoria Regional
Oncology imagingVictoria Regional, NZ, PET sites
Women's health (obstetric, gynaecological, breast)Women's Imaging (Tas), NZ
Cardiac imagingVictoria Regional
Lung cancer screeningGroup-wide, under NLCSP

Service platforms

PlatformDescriptionLaunchScale (latest)
IDXt teleradiologyUrgent, routine and overflow reporting across all modalities for IDX, private practices and public hospitals2,020143 teleradiologists (30 Jun 2026); reporting volumes up >30% vs FY25; ~15% of group scans
AI-assisted reportingAI tools used in ~10% of scans under a structured AI governance framework—~10% of scans
Comprehensive hospital-based practicesIntegrated orthopaedic imaging inside specialist hospitalsFY26Eastwood Private Hospital (SA, opened FY26); Maroochy Private Hospital (Qld, now open)

Brand register

BrandRegionOrigin
Lake ImagingVic RegionalLegacy IDX
The X-Ray GroupVic RegionalLegacy Capitol (per business unit listing)
Capital RadiologyVic MetroLegacy Capitol
FMIGVic MetroLegacy Capitol
Imaging @ Olympic ParkVic MetroLegacy Capitol
Imaging QueenslandQldLegacy IDX (acquisition; earn-out outstanding)
South Coast RadiologyQldLegacy IDX
Apex RadiologyWALegacy IDX
Radiology TasmaniaTasLegacy Capitol
Women's ImagingTasLegacy Capitol
Fowler Simmons RadiologySALegacy Capitol
Astra RadiologyNZLegacy IDX (third-party data lists "Ascot Radiology"; possible rebrand)
Trinity MRINZLegacy IDX
SRG RadiologyNZLegacy IDX
Horizon RadiologyNZLegacy IDX (FY23 acquisition)
IDXtANZInternal start-up (2020)

Financial Narrative

Income statement: notes and sources

Sources: FY22 Annual Report (FY22 operating revenue); FY24 Results release (FY23–FY24); FY26 Annual Report (FY25 restated, FY26). FY22 dividend derived: FY23 dividend of 6.0c was reported as down 14% on FY22 (FNArena) and FY22 final was 3.0c (FY22 Appendix 4E), consistent with a 7.0c total. Gross profit is not reported — IDX presents expenses by nature (employee, consumables, occupancy etc.), so gross profit is "not publicly disclosed".

Margins

FY23–FY24 EBITA and NPAT margins derived; FY25–FY26 operating NPAT margin and payout from FY26 Annual Report.

Growth

FY23 revenue growth derived from 358.7 → 440.8 (FNArena reported ~22% using rounded figures). Revenue CAGR FY22–FY26: ~21.8% (derived; FY22 base is "operating revenue"). Revenue CAGR FY23–FY26: ~21.4% (derived). The CAGR is overwhelmingly acquisition-driven; Australian organic growth has run at ~7–9% per annum.

Commentary. The five-year record has three distinct phases. FY22–FY23 was a COVID and cost-inflation trough: FY22 revenue grew only 2.8% and operating EPS almost halved, and Jarden noted EBITDA margins fell every half for two years to an 18.5% nadir in 1H FY23. FY24 was a stabilisation year marred by the A$71.6m New Zealand impairment, which swung statutory NPAT to a A$60.7m loss even as operating EBITDA margin edged up to 19.5% and a strong 2H (20.3% margin) set up recovery. FY25–FY26 is the merger phase: Capitol added ~A$127m of revenue in FY25 (part-year) and the full-year effect drove FY26 revenue to A$788.7m, while A$14m+ of synergies and fixed-cost leverage lifted operating EBITDA margin 160 bps across two years. The persistent gap between operating and statutory profit (A$25.4m in FY26) reflects integration, restructuring and amortisation; the board expects the gap to narrow significantly beyond FY26. EPS growth (23.6% in FY26) lags NPAT growth (50.1%) because the share count rose ~60% with the merger scrip.

Balance sheet

Sources: FY24 Results release; FY26 Annual Report (FY25 restated). Net debt includes A$6.5m of bank guarantees and excludes A$1.9m capitalised borrowing costs (FY26). Current borrowings shown as nil because no current borrowings line appears in the FY26 summary balance sheet. FY25 working capital derived from FY26 movement disclosure (increase of A$1.3m to −A$66.0m). Net tangible assets per share were negative (−105.56c at 30 Jun 2026; units as reported in Appendix 4E), reflecting goodwill-heavy acquisition accounting.

Commentary. The merger doubled equity (A$301.7m → A$692.0m) via scrip while net debt rose ~A$115m as Capitol's debt was refinanced into the group facility. Intangibles now represent ~59% of total assets (A$846.8m / A$1,427.4m), so book value is dominated by goodwill and brands; tangible equity is negative. The balance sheet is nonetheless serviceable: 2.3x covenant leverage, A$117m undrawn committed headroom, a further A$200m uncommitted, and a facility tenor to December 2029. Negative working capital (−A$66m) is structural — patients pay at or near point of service while staff and suppliers are paid in arrears.

Cash flow

Sources: FY24 Results release; FY26 Annual Report cash flow summary; FY25 statutory operating cash flow from FNArena (secondary). Company "operating free cash flow" = operating EBITDA ± non-cash items ± working capital − lease principal − replacement capex (pre-tax, pre-interest, pre-growth capex). No buyback has been announced in the period reviewed. Transaction and integration costs paid derived: FY25 20.6 + 11.3; FY26 3.3 + 16.3.

Commentary. Company-defined free cash flow nearly doubled from A$53.1m (FY23) to A$106.4m (FY26), tracking EBITDA. After tax, interest, growth capex, dividends and A$19.6m of integration cash costs, FY26 net cash flow was roughly break-even (+A$0.4m), which is why net debt was flat despite strong operating cash generation. As integration costs fade in FY27, the same operating cash flow should translate into genuine de-gearing — the key test of the "de-gearing" outcome in IDX's strategy.

Ratios

FY25 and FY26 net debt/equity reported; FY23–FY24 derived. ROE, ROA, asset turnover, interest cover and receivable days derived by this analyst from disclosed figures. Cash conversion cycle is not meaningful for a services business with minimal inventory and is not disclosed; receivable days (~14) indicates fast collection. Covenant leverage uses pre-AASB 16 LTM EBITDA of A$129.6m (FY26) and A$116.4m (FY25).

Commentary. Returns remain modest. A 7.6% ROIC on operating EBIT is likely below or near the company's weighted average cost of capital, which is the central bear point on the merger: the deal created scale and synergies, but goodwill-heavy capital has not yet produced compelling returns. The positive is the direction of travel — ROIC, margin and interest cover all improved in FY26, and interest cost fell almost 90 bps with 51.2% of gross debt hedged from late December 2025.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Financial Detail

Revenue by Segment

Metric (AUD Mn)FY24FY25FY26

Legacy IDX revenue

469.7501.2—

Legacy Capitol revenue (from 20 Dec 2024)

0126.8—

Consolidated revenue and other income

469.7628.0788.7

Legacy IDX operating NPAT

18.119.6—

Legacy Capitol operating NPAT

012.0—

Consolidated operating NPAT

18.131.647.4

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Revenue by Segment (%) and Segment Margins & Growth (%)

Metric (%)FY24FY25FY26

Legacy IDX revenue contribution

10079.8—

Legacy Capitol revenue contribution

020.2—

Legacy IDX Australian organic revenue growth

7.27.38.9

Legacy Capitol organic revenue growth

—5.25.4

Revenue by Segment and Segment Margins & Growth (%)

Metric (AUD Mn)1H FY252H FY251H FY262H FY26

Revenue and other income

252.9375.1393.5395.2

Operating EBITDA

——81.183.7

Operating EBITDA margin (%)

——20.621.2

Business Units

Business unitKey brandsTotal clinicsComprehensive clinicsStrategic role

Victoria – Metro

Capital Radiology, FMIG

4523

Community imaging, large GP base, rising specialist mix

Victoria – Regional

Lake Imaging, The X-Ray Group

177

Hospital and community imaging in western Victoria; MSK, oncology, cardiology, breast

Victoria – IOP

Imaging @ Olympic Park

11

National MSK centre of excellence; elite sport; integrated imaging and day procedure centre

Queensland

Imaging Queensland, South Coast Radiology

4017

Gold Coast, Sunshine Coast, Brisbane, Central Qld

Western Australia

Apex Radiology

124

Largest regional diagnostic service in WA; small but growing Perth presence

Tasmania

Radiology Tasmania, Women's Imaging

53

State's leading community imaging provider

South Australia

Fowler Simmons Radiology

22

MSK centre of excellence; Eastwood Private Hospital clinic

New Zealand

Astra Radiology, Trinity MRI, SRG Radiology, Horizon Radiology

195

Greater Auckland; neuro, MSK, oncology, breast; largest obstetric scan provider in NZ

Teleradiology

IDXt

——

143 reporting radiologists (114 at 30 Jun 2025)

Total

—

141 listed (142 reported)

62

—

Income Statement and Per-Share Data

MetricFY22FY23FY24FY25FY26

Revenue and other income (AUD Mn)

358.7440.8469.7628.0788.7

Operating EBITDA (AUD Mn)

—85.291.5126.5164.8

Operating EBITA (AUD Mn)

—43.846.170.097.1

Operating NPAT (AUD Mn)

—17.918.131.647.4

Statutory NPAT (AUD Mn)

—25.0-60.72.822.0

Operating diluted EPS (AUD cents)

—7.67.710.212.6

Statutory basic EPS (AUD cents)

———0.95.9

Statutory diluted EPS (AUD cents)

———0.95.8

Dividends declared per share (AUD cents)

7.06.05.86.59.3

Margin Analysis (%)

Metric (%)FY23FY24FY25FY26

Operating EBITDA margin

19.319.520.120.9

Operating EBITA margin

9.99.811.112.3

Operating NPAT margin

4.13.95.06.0

Statutory net margin

5.7-12.90.42.8

Dividend payout on operating NPAT

—74.476.373.0

Margin Analysis (%) (FY22–FY26)

Metric (%)FY22FY23FY24FY25FY26

Revenue growth YoY

2.822.96.633.725.6

Operating EBITDA growth YoY

——7.438.330.3

Operating NPAT growth YoY

——1.377.450.1

Operating diluted EPS growth YoY

-46.2—1.032.923.6

Balance Sheet

MetricFY23FY24FY25FY26

Total assets (AUD Mn)

——1,424.61,427.4

Cash and equivalents (AUD Mn)

—42.452.151.3

Borrowings – non-current (AUD Mn)

——341.3341.8

Borrowings – current (AUD Mn)

——00

Lease liabilities – current (AUD Mn)

——20.321.5

Lease liabilities – non-current (AUD Mn)

——223.4233.9

Net debt pre-AASB 16 (AUD Mn)

194.5183.5298.0298.9

Total equity (AUD Mn)

373.0301.7692.0681.5

Intangible assets incl. goodwill (AUD Mn)

——861.7846.8

Property, plant and equipment (AUD Mn)

——243.0248.5

Right-of-use assets (AUD Mn)

——224.6228.5

Total current assets (AUD Mn)

——95.399.4

Total current liabilities (AUD Mn)

——142.0148.6

Working capital as reported (AUD Mn)

——-64.7-66.0

Committed debt facilities (AUD Mn)

—353.7—467.4

Undrawn committed facilities (AUD Mn)

—128.5—117.0

Cash Flow and Margin Analysis (%)

MetricFY22FY23FY24FY25FY26

Statutory net operating cash flow (AUD Mn)

———73.8—

Operating free cash flow – company definition (AUD Mn)

—53.156.081.4106.4

Replacement capex (AUD Mn)

———28.028.8

Growth capex (AUD Mn)

——9.327.321.0

Total capex (AUD Mn)

——23.955.349.8

Lease principal payments (AUD Mn)

———18.420.7

Tax paid (AUD Mn)

———4.013.7

Interest and borrowing costs paid incl. leases (AUD Mn)

———29.627.6

Dividends paid – cash (AUD Mn)

———15.525.8

Dividends paid incl. DRP (AUD Mn)

——13.816.827.0

Transaction and integration costs paid (AUD Mn)

———31.919.6

Share buybacks (AUD Mn)

00000

FCF conversion before replacement capex (%)

—92.977.286.582.0

Financial Ratios (x) and Returns & Leverage Ratios (%)

RatioFY23FY24FY25FY26

Net debt / EBITDA pre-AASB 16 (x)

2.92.62.62.3

Net debt / equity (%)

52.160.842.943.9

Gross borrowings / equity (x)

——0.490.50

Current ratio (x)

——0.670.67

ROIC on operating EBIT – company (%)

——7.37.6

ROE statutory, average equity (%)

—-18.00.63.2

ROE operating, average equity (%)

—5.46.46.9

ROA statutory (%)

———1.5

Asset turnover (x)

———0.55

Operating EBIT / cash interest incl. leases (x)

——2.43.5

Weighted avg interest rate on core debt (%)

——6.245.36

Receivable days (days)

———14

Region Margins & Growth (%) and Revenue by Region (%)

Metric (%)FY24FY25FY26

Australia organic revenue growth (legacy IDX)

7.27.38.9

Australia organic revenue growth (group, all sources)

7.2—7.4

Medicare benefits growth, comparable reference

9.7—9.4

New Zealand organic revenue growth (constant currency)

5.31.42.1

Australia average fee per exam growth

7.7—6.5

Medicare indexation applied 1 July

3.6—2.4

Region Overview

RegionClinicsComprehensiveShare of group clinics (%)

Victoria (Metro + Regional + IOP)

633144.7

Queensland

401728.4

Western Australia

1248.5

New Zealand

19513.5

Tasmania

533.5

South Australia

221.4

Share Price History

DatePrice (AUD)Source

26 Aug 2025 (FY25 result release)

2.72

InvestSMART

14 Jan 2026

2.65

FNArena

26 Mar 2026

2.41

FNArena

24 Jun 2026 (Chair purchase)

~1.96

Motley Fool insider data

22–28 Jul 2026

2.05–2.08

Motley Fool price history

10 Aug 2026 (pre-release)

2.18

InvestSMART

2 Sep 2026

2.35

InvestSMART

30 Sep 2026

2.16

InvestSMART

Market Valuation and Per-Share Data

MetricFY24FY25FY26

Market capitalisation at 30 June (AUD Mn)

624.7946.0746.1

Dividends declared per share (AUD cents)

5.86.59.3

Valuation Snapshot

MultipleValueBasis

P/E (operating, FY26)

~17.1x

216c / 12.6c

P/E (statutory diluted, FY26)

~37x

216c / 5.8c

EV/EBITDA (pre-AASB 16)

~8.5x

(805 + 298.9) / 129.6

EV/EBITDA (post-AASB 16, incl. leases)

~8.2x

(805 + 298.9 + 255.4) / 164.8

EV/Sales

~1.4x

(805 + 298.9) / 788.7

P/B

~1.18x

805 / 681.5

Dividend yield (FY26 declared, fully franked)

~4.3%

9.3c / 216c

Per-Share Data

Metric (AUD cents)FY22FY23FY24FY25FY26

Interim dividend

4.02.52.52.53.3

Final dividend

3.03.53.34.06.0

Total dividend

7.06.05.86.59.3

Maturity Year Details

Maturity yearCommitted facilities maturing (AUD Mn)

FY27–FY29

0

FY30 (Dec 2029)

467.4

Analyst Conclusions

Management guidance (FY27)

  • Continued revenue growth; operating EBITDA margin improvement to >21.0%.

  • Capex of A$50–60m.

  • Continued de-gearing within a 2.0–2.5x target range.

  • Statutory-to-operating earnings gap expected to narrow significantly beyond FY26.

  • No quantitative revenue or NPAT guidance.

Consensus expectations

Inputs suggest a FY27 baseline of: Medicare indexation 2.6% + volume growth + mix shift (FY26 average fee per exam +6.5%), implying high-single-digit organic revenue growth if Australia tracks recent rates, and margin expansion from a 2H FY26 exit rate of ~21.2% (derived).

Bull case

  1. Margin runway is already visible. The 2H FY26 margin of ~21.2% (derived) exceeds the >21% target before FY27's A$-scale procurement savings, 2.6% indexation and new-site ramp-up; every 100 bps of margin on ~A$840m of revenue adds ~A$8m of EBITDA.

  2. Integration costs roll off, cash flows to equity. FY26 carried A$19.6m of cash transaction and integration costs; as these fade, A$100m+ of operating FCF should drive genuine de-gearing toward 2.0x and support dividend growth.

  3. Regulatory tailwinds stack up. NLCSP spend expected to grow >50% p.a. for three years (IDX's share ~14% vs 12% market share), and full MRI deregulation in July 2027 lets IDX monetise its 62 comprehensive sites.

Bear case

  1. Share loss is real. Group Australian organic growth (7.4%) trailed Medicare (9.4%) in FY26; legacy Capitol grew only 5.4%. A larger network growing slower than the market is a strategic problem, not a timing issue.

  2. Returns do not cover the merger's cost. ROIC is 7.6% on a goodwill-heavy base (A$846.8m intangibles; negative NTA); statutory ROE is ~3%. Deregulation also arms competitors with MRI capacity in IDX's markets.

  3. Execution and leadership risk. A new CEO and CFO arriving within two months, a possible NZ divestment, ongoing system consolidation, and an FY26 EPS outcome (12.6c) below prior broker forecasts (13.3–13.4c) raise the risk of a reset at the AGM or 1H FY27 result.

Catalysts and monitorables (next 12 months)

TimingCatalyst / monitorableWhat to watch
29 Oct 2026AGMTrading update for 1Q FY27; any quantitative guidance; first public view of Martinez's priorities
~Early Nov 2026Completion of CEO 90-day reviewCost-out program, portfolio decisions, technology roadmap
Nov 2026Employee engagement surveyCulture post-integration and leadership change
H2 CY2026NZ strategic reviewConfirmation, outcome, valuation and use of proceeds
Feb 20271H FY27 resultsMargin vs >21%; organic growth vs Medicare; statutory/operating gap; leverage
1 Jul 2027Full MRI deregulationIDX capex plans and competitor MRI announcements
OngoingMonthly Medicare DI statisticsMarket growth vs IDX organic rates
OngoingIDXt radiologist count and external revenueProductivity lever
OngoingSubstantial-holder noticesRegister stability after WAM/Challenger exits

Analyst verdict

Integral Diagnostics has completed the hard part of its transformation: the Capitol Health merger is integrated, synergies have beaten the original target by more than 40%, operating EBITDA margin has climbed to 20.9% with a second-half exit rate above 21%, and operating free cash flow now exceeds A$100m a year. The balance sheet, at 2.3x covenant leverage with headroom to 2029, is no longer a constraint, and the regulatory backdrop — indexation of 2.6%, lung cancer screening scaling rapidly, and full MRI deregulation in mid-2027 — is the most supportive the sector has seen in a decade.

The equity story, however, has shifted from "can they integrate?" to "can they grow at or above the market with acceptable returns?". On that question the evidence is mixed. Group Australian organic growth lagged Medicare by two percentage points in FY26, the legacy Capitol network is under-earning, New Zealand remains a low-growth drag that may be divested, and a 7.6% ROIC on a goodwill-laden base means the merger has so far created scale more than value. The simultaneous arrival of a new CEO and CFO adds both opportunity and risk: Jason Martinez brings direct experience of running I-MED's largest regions and has publicly committed to margin, workforce and culture, but strategic resets frequently bring "kitchen-sink" provisions and revised targets.

At roughly 17x operating earnings, ~8.5x pre-AASB 16 EV/EBITDA and a ~4.3% fully franked yield, the valuation embeds limited optimism after a ~16–20% share price decline over the past year, and consistent insider buying near A$2.00 is a supportive signal. Our assessment: constructive but conditional. The investment case strengthens materially if the October AGM and the February 2027 half-year confirm margin above 21%, organic growth converging on Medicare, a clear NZ decision and a visible decline in statutory adjustments. Failure on growth versus market would leave IDX a cash-generative but structurally low-return roll-up.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Executive Leadership

Executive Leadership Team

NameTitleTenurePrior rolesEducation

Jason Martinez

Managing Director & CEO

From 6 Aug 2026 (appointment announced 10 Nov 2025)

EGM NSW, ACT and WA at I-MED Radiology (2015–2025); COO and Executive Director at Konekt (now APM Group); Head of Specialist Services Medical Centres at Healius; Practice Director at Ineum Consulting; Chartered Accountant

BCom, GAICD

Jenny Martin

Chief Financial Officer

From 5 Oct 2026

——

Craig White

Outgoing CFO (transition to 31 Oct 2026)

Long-serving; transformed finance, risk and legal functions; also held COO responsibilities for a period (per 10 Aug 2026 release)

——

Dr Ian Kadish

Former MD & CEO (retired 6 Aug 2026)

22 May 2017 – 6 Aug 2026

CEO Pulse Health; CEO Healius Pathology; COO Greencross; Netcare executive director; McKinsey

University of the Witwatersrand; MBA, Wharton

John Merity

Company Secretary

———

Chief Medical Officer, Chief Information Officer, Chief People Officer

Executive roles listed in FY26 Annual Report

———

“—” = not publicly disclosed.

Board of Directors

NameRoleAppointedIndependentKey experienceCommitteesIDX shares

Toby Hall

Chair

Director 28 Sep 2023; Chair 29 Nov 2023

Yes

Group CEO, St Vincent's Health Australia (2014–2022); NED Ingenia Communities, Siloam International Hospitals

Chair Nomination; Audit; PCR

276,571

Jason Martinez

MD & CEO

6 Aug 2026

No (executive)

See above

—

Nil

Andrew Fay

NED

18 Jul 2022

Yes

Ex-CEO/CIO Deutsche Asset Management (Australia); Chair Growthpoint Properties Australia

Chair PCR; Audit; Nomination

85,000

Ingrid Player

NED

29 Aug 2023

Yes

Former Group Executive Legal, Governance and Sustainability at a major Australian healthcare provider; NED Cleanaway, Cogstate

Chair RCS; Audit; PCR; Nomination

60,000

Laura McBain

NED

20 Dec 2024

Yes

Ex-MD Bellamy's Australia, Maggie Beer Holdings; ex-Capitol NED

Chair Audit (from Mar 2026); RCS

23,250

Dr Kevin Shaw

NED

20 Dec 2024

Yes

Radiologist; Director of Medical Imaging, Barwon Health; ex-Capitol NED

RCS; PCR

28,000

Dr Manish Mittal

Non-Executive Radiologist Director

5 Feb 2025

No (employed radiologist; IDXt Clinical Director)

18+ years in IDX and predecessor practices; MRI focus

RCS

2,122,908

Major Shareholders

HolderStake (%)SharesDate / source

Australian Retirement Trust

5.04318,811,967

Substantial notice, crossed 29 May 2026 (FilingReader summary)

The Vanguard Group

5.12419,051,852—

Challenger Limited (CGF) and associates

Became substantial at 5.40%; later ceased; further change notice 4 Sep 2026

—

TipRanks; InvestSMART announcements list

Wilson Asset Management (WAM/WAX/WMI)

Ceased to be substantial 17 Sep 2026

—

InvestSMART announcements list

Unnamed new substantial holder

≥5

—

"Becoming a substantial holder", 23 Jun 2026

Competitive Landscape

Key Competitors

CompetitorOwnershipGeographyPositioning vs IDX

I-MED Radiology Network

Private equity (Permira)

National (Australia)

Largest Australian imaging network; IDX's new CEO came from I-MED

Sonic Healthcare – Sonic Imaging (incl. Queensland X-Ray and other brands)

Listed (ASX: SHL)

National; overlaps Qld and Vic

Diversified pathology/imaging giant with scale purchasing

Lumus Imaging

Divested by Healius in 2024 to private equity (Affinity Equity Partners — verify)

NSW, Vic, Qld, WA

Large multi-state competitor

Qscan Group

Private

Qld, NSW, WA, Vic

Direct competitor in Qld

Perth Radiological Clinic

Private

WA

Perth metro incumbent

Envision Medical Imaging / SKG Radiology

Private / group-owned

WA

Perth competitors

PRP Diagnostic Imaging

Private

NSW

Limited overlap

Hospital-based public radiology (state health services)

Public

All states

Competes for complex work; also a customer for teleradiology

Mercy Radiology / Pacific Radiology / Auckland Radiology Group

Private

New Zealand

Auckland competitors; referrer-owned practices hurt IDX NZ

Everlight Radiology and other teleradiology providers

Private

ANZ / international

Compete with IDXt

Competitor Detail

MetricIDX FY26

Revenue (AUD Mn)

788.7

Revenue growth (%)

25.6

Operating EBITDA margin (%)

20.9

Clinics

142

Australian market share (%)

~12

Company Snapshot

3,049

Employees

2008

Founded

East Melbourne, Australia

Headquarters

SWOT Analysis

Strengths

  • Margin recovery delivered: operating EBITDA margin rose from 19.3% (FY23) to 20.9% (FY26), with 2H FY26 at ~21.2% (derived).
  • Synergy over-delivery: A$14.0m+ of annual merger synergies against a ≥A$10m original target (FY26 Results).
  • Cash generation: operating free cash flow of A$106.4m in FY26, up 30.7%, at 82.0% conversion.
  • High-acuity capacity: 42 licensed MRIs (from 23) and 62 comprehensive sites.
  • Teleradiology platform: IDXt grew to 143 radiologists with >30% volume growth in FY26.
  • Clinical quality metrics: patient NPS +81; 100% site accreditation; incidents 0.04% of exams.
  • Lung screening outperformance: ~14% NLCSP share against ~12% overall market share.

Weaknesses

  • Low statutory profitability: statutory NPAT A$22.0m vs operating A$47.4m in FY26; A$25.4m of post-tax non-operating items.
  • Modest returns: ROIC 7.6% (FY26); statutory ROE ~3.2% (derived).
  • Goodwill-heavy balance sheet: intangibles A$846.8m; negative NTA per share.
  • Below-market organic growth: group Australia organic 7.4% vs Medicare 9.4% (FY26).
  • NZ underperformance: A$71.6m impairment (FY24) and 1.4–2.1% organic growth (FY25–FY26).
  • Network contraction: clinics fell from ~155 at merger to 142, with closures and a divestment.
  • Current ratio 0.67x — structurally low liquidity ratios (mitigated by A$117m undrawn facilities).

Opportunities

  • Full MRI deregulation from 1 Jul 2027: CEO explicitly targets this using scale.
  • NLCSP growth: spend expected to rise >50% p.a. for three years, with downstream PET and interventional work.
  • FY27 indexation of 2.6% plus continued mix shift (average fee per exam +6.5% in FY26).
  • Further procurement savings flagged for FY27.
  • Overseas radiologist pathways to ease workforce constraints from July 2026.
  • Narrowing statutory/operating gap as integration costs (A$19.6m pre-tax in FY26) roll off.
  • Portfolio optimisation of NZ (unconfirmed strategic review) could lift group growth and returns.

Threats

  • Competitor MRI build-out post-deregulation eroding IDX's licence advantage.
  • Radiologist and sonographer shortages — staff turnover 20.5% (FY26).
  • Government reimbursement risk: indexation below wage inflation; PET excluded from FY26 indexation.
  • Execution risk from simultaneous CEO and CFO change (Aug–Oct 2026).
  • Cyber and privacy risk: healthcare data breaches are a sector-wide threat; IDX lists information security as a principal risk.
  • Referrer-owned practices (demonstrated in Auckland) diverting referrals.
  • Share register churn: WAM and Challenger exits in 2026 could weigh on liquidity and price.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Key Developments

DateEventSignificance
1 Jul 2025NLCSP launches; partial MRI deregulation; IDX licensed MRIs rise from 23 to 42; Medicare indexation +2.4%Structural tailwinds to high-value modalities
Jul 2025Group July revenue +7.0% (working-day and like-for-like adjusted)Strong start to FY26
26 Aug 2025FY25 results: revenue A$628.0m, operating NPAT A$31.6m (+77.4%), operating EPS +32.9%; synergy target raised to A$14m; dividend 6.5cMerger delivering; share price fell sharply over subsequent months
Oct–Nov 20252025 AGM; FY26 EBITDA margin guidance of ~21.0% reaffirmedGuidance anchor
Q1 FY26Like-for-like Australian revenue up 8.3% (Ord Minnett commentary)MRI deregulation effect
1 Nov 2025GP Bulk Billing Incentive expanded to all AustraliansSupports GP referrals, particularly for legacy Capitol
10 Nov 2025Jason Martinez named next MD & CEOLeadership succession
Late Dec 202551.2% of gross debt hedged at rates favourable to BBSYLower interest cost
15 Jan 2026FY26 results date set for 25 Aug 2026Routine
Jan 2026Group revenue +7.8% constant currencyMomentum
24 Feb 20261H FY26 results: revenue A$393.5m (+55.6%), operating EBITDA A$81.1m (~3% above consensus per Jarden), margin 20.6%; FCF conversion fell to 65% on working capital (Bell Potter)Mixed: earnings beat, cash conversion softer
27 Feb–9 Mar 2026On-market buying by directors Shaw, Player, McBain and HallInsider confidence
2 Apr 2026Interim dividend 3.3c paidShareholder returns
25 Mar 2026Martinez start date confirmed as 6 Aug 2026 after extended garden leave from I-MEDKadish to continue until handover
31 Mar 2026Raelene Murphy resigns; McBain becomes Audit ChairBoard refresh
30 Apr–29 May 2026Australian Retirement Trust becomes substantial holder (5.04%)Institutional accumulation
Jun 2026Chair Hall buys 12,000 (11 Jun) and 51,300 shares (24 Jun at ~A$1.96)Buying near 52-week lows
23 Jun 2026New substantial holder noticeRegister rotation
1 Jul 2026Medicare indexation 2.6% for FY27; expedited specialist pathway for Canadian radiologists effectiveRevenue and workforce tailwinds
Jul 2026Limited-scope pathway for overseas-trained radiologists announcedEases radiologist shortage
6 Aug 2026Martinez commences; Kadish retiresNew era
10 Aug 2026Preliminary FY26 results in line with guidance; Jenny Martin appointed CFO; share price up ~6% on the dayDe-risked result
13 Aug 2026Change in substantial holdingRegister rotation
20 Aug 2026AGM date set for 29 Oct 2026Upcoming catalyst
25 Aug 2026FY26 results: revenue A$788.7m, operating EBITDA A$164.8m (20.9%), operating NPAT A$47.4m, dividend 9.3c (+43%; final +50%); first AASB S2 report; FY27 capex A$50–60mSolid; FY26 operating EPS of 12.6c below earlier broker forecasts of 13.3–13.4c
25 Aug 2026Third-party call summary cites strategic review of NZ (unconfirmed)Potential portfolio change
28 Aug 2026Ex-dividend; performance rights issued/lapsed (unquoted securities notices)Routine
4 Sep 2026Substantial holding changes, including Challenger (CGF)Register rotation
17 Sep 2026Wilson Asset Management ceases to be substantial holderSelling by a prior holder
2 Oct 2026Final dividend 6.0c paid; DRP operatedShareholder returns
5 Oct 2026Jenny Martin assumes CFO; Craig White remains until 31 OctFinance transition

Financial Performance

Explore key financial metrics, segmented revenue, balance sheet health, and performance trends.

Revenue

4 charts
Revenue by Segment (FY2024–FY2026): Legacy IDX revenue rose from AUD 469.7 Mn in FY2024 to AUD 501.2 Mn in FY2025.
Integral Diagnostics Limited — Revenue by Segment (FY2024–FY2026)
Series (AUD Mn)FY2024FY2025FY2026
Legacy IDX revenue469.7501.2—
Legacy Capitol revenue (from 20 Dec 2024)0126.8—
Consolidated revenue and other income469.7628788.7
Legacy IDX operating NPAT18.119.6—
Legacy Capitol operating NPAT012—
Consolidated operating NPAT18.131.647.4

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Sources

Sources

  1. IDX FY26 Results ASX release, 25 Aug 2026 (announcements.asx.com.au)
  2. IDX FY26 Annual Report and Appendix 4E, 25 Aug 2026 (announcements.asx.com.au)
  3. IDX Preliminary FY26 Results and CFO appointment, 10 Aug 2026 (announcements.asx.com.au)
  4. IDX Start for New MD & CEO, 6 Aug 2026 (announcements.asx.com.au)
  5. IDX Commencement Date for New MD & CEO, 25 Mar 2026 (bulletin.webull.com)
  6. IDX 1H FY26 Results, 24 Feb 2026 (announcements.asx.com.au)
  7. IDX FY25 Results, 26 Aug 2025 (announcements.asx.com.au)
  8. IDX FY24 Results, 27 Aug 2024 (announcements.asx.com.au)
  9. IDX / Capitol Merger Implementation Deed release, 18 Jul 2024 (announcements.asx.com.au)
  10. IDX / Capitol Merger Process Deed release, 17 Jun 2024 (announcements.asx.com.au)
  11. IDX FY22 Annual Report, 29 Aug 2022 (announcements.asx.com.au)
  12. Reuters brief: IDX completes merger with Capitol Health, 20 Dec 2024 (www-web.itiger.com)
  13. Maddocks: Capitol Health merger case note (maddocks.com.au)
  14. ROIC.ai company profile (roic.ai)
  15. Quartr: IDX H2 2026 earnings summary (quartr.com)
  16. SmallCaps: FY26 results coverage (smallcaps.com.au)
  17. Motley Fool Australia: FY26 preliminary and final results coverage · fool.com.au
  18. Motley Fool Australia ticker page (price history, insider trades) (fool.com.au)
  19. InvestSMART IDX profile and announcements · investsmart.com.au
  20. FNArena IDX stock analysis · FY23 coverage
  21. FilingReader: Australian Retirement Trust substantial holding (filingreader.com)
  22. TipRanks: Vanguard, Challenger substantial holding notices; FY25 results · tipranks.com
  23. MarketScreener: Ian Kadish insider profile (in.marketscreener.com)
  24. IBISWorld company profile (ibisworld.com)
  25. Kalkine Media: CEO commencement coverage (kalkinemedia.com)

Unlock Company Contacts

Connect with Key Decision-Makers

Access verified employee contacts and decision-maker information from this company to support your sales, lead generation, and business development efforts.